Open-label, randomized, multiple-center, parallel study comparing glycemic responses and safety profiles of Glucerna versus Fresubin in subjects of type 2 diabetes mellitus.
Since the increase of prevalence of type 2 diabetes mellitus (T-2DM), the replacing quickly absorbed carbohydrates with a fat source rich in monounsaturated fatty acid to provide improved glycemic control in these patients has become an important assistant therapy. In the present study, we compared glycemic response and safety of two nutritional products, Glucerna and Fresubin, in Chinese subjects with T-2DM. Overall, 203 T-2DM subjects were randomly assigned (1:1) to either Glucerna or Fresubin. The primary endpoint was the adjusted area under the curve (adj-AUC) for plasma glucose at 0-240 min. Blood samples were collected at 0, 30, 60, 90, 120, 180, and 240 min to compare the adjusted area under the curve (AUC) for the change in plasma glucose or insulin from 0 to 240 min. Adjusted peak values and times of glucose and insulin responses and adjusted glucose and insulin values were collected at the same time points. Safety parameters were also evaluated. The adjusted AUC for the change in plasma glucose in the Glucerna group was significantly lower than in Fresubin group (5.60 +/- 5.88 mmol/l*h vs. 7.97 +/- 6.32 mmol/l*h, P = 0.0061), as was the adjusted peak value of glucose (3.51 +/- 2.04 mmol/l vs. 4.69 +/- 1.99 mmol/l, P < 0.0001). Glucerna subjects had a longer adjusted peak time to insulin response compared to Fresubin subjects (105.00 +/- 43.4 min vs. 88.81 +/- 37.69 min, P = 0.0050). Glucerna subjects also experienced more gradual changes in glucose and insulin values. In conclusion, Glucerna provided better control of postprandial plasma glucose and insulin levels in Chinese subjects with T-2DM. Variation of postprandial glucose tended to be relatively stable after patients took Glucerna. Study results suggest that Glucerna may be beneficial in the reduction of postprandial glycemia.
Wang
Wei-Qing
WQ
Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Jiaotong University Medical School, Ruijin 2nd Road 197, Shanghai, 200025, P.R. China.
Zhang
Yi-Fei
YF
Zhou
Da-Jin
DJ
Liu
Zhi-Min
ZM
Hong
Xu
X
Qiu
Ming-Cai
MC
Shi
Yong-Quan
YQ
Xia
Pei-Jin
PJ
Lu
Jin
J
Xu
Mao-Jing
MJ
An
Liang
L
Feng
Wei
W
Zhang
Peng
P
Schwamman
J
J
Ning
Guang
G
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000178:diet therapy*; D004040:Dietary Carbohydrates / Q000627:therapeutic use*; D004042:Dietary Fats, Unsaturated / Q000627:therapeutic use*; D004044:Dietary Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005526:Food, Formulated / Q000009:adverse effects; D038321:Glycemic Index / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D017060:Patient Satisfaction
D001786:Blood Glucose; D004040:Dietary Carbohydrates; D004042:Dietary Fats, Unsaturated; D004044:Dietary Proteins; C048418:Fresubin; C530986:Glucerna; D007004:Hypoglycemic Agents